Adherence to adalimumab therapy in Crohn's disease: A French multicenter experience

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 152-159

  Billioud, Vincent ^a   Laharie, David ^b   Filippi, Jérôme ^c   Roblin, Xavier ^d   Oussalah, Abderrahim ^a   Chevaux, Jean Baptiste ^a   Hébuterne, Xavier ^c   Bigard, Marc André ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

adalimumab; adherence; Crohn's disease

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; ARTICLE; CROHN DISEASE; DISEASE DURATION; DRUG DOSE INCREASE; FEMALE; FRANCE; HOSPITALIZATION; HUMAN; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; PREGNANCY; PRIORITY JOURNAL; TRAVEL; TREATMENT FAILURE; UNIVERSITY HOSPITAL;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650149614     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21491     Document Type: Article

References (35)

1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2009; 105: 289-297.
2. Van Assche G, Vermeire S, Rutgeerts P., The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010; 7: 79-85.
3. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003.
4. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96: 2929-2933.
5. Loftus EV Jr., A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006; 12: 1107-1113.
6. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996; 8: 1179-1183.
7. Shale MJ, Riley SA., Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 191-198.
8. van Hees PA, van Tongeren JH., Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol. 1982; 4: 333-336.
9. Bloomfeld RS, Onken JE., Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther. 2003; 17: 69-73.
10. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther. 2007; 26: 217-225.
11. Mantzaris GJ, Roussos A, Kalantzis C, et al. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission ? Inflamm Bowel Dis. 2007; 13: 446-450.
12. Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut. 2004; 53: 1123-1128.
13. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644-653.
14. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
15. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
16. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250. (Pubitemid 47080388)
17. Peyrin-Biroulet L, Desreumaux P, Stalgis C, et al. Achieving long-term maintenance of remission in Crohn's disease: are all anti-TNF created equal? Gut. 2006; 55: A131.
18. Allen PB, Lindsay H, Tham TC,. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol. 2010; 10: 1.
19. Kane S, Shaya F., Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008; 53: 1020-1024.
20. Kane SV, Chao J, Mulani PM., Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009; 26: 936-946.
21. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114: 39-43.
22. Kane S, Dixon L., Adherence rates with infliximab therapy in Crohn's disease. Aliment Pharmacol Ther. 2006; 24: 1099-1103.
23. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-753.
24. DeLong ER, DeLong DM, Clarke-Pearson DL., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44: 837-845.
25. Plosker GL, Lyseng-Williamson KA., Adalimumab: in Crohn's disease. BioDrugs. 2007; 21: 125-132.
26. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009; 137: 1628-1640.
27. Borah BJ, Huang X, Zarotsky V, et al. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin. 2009; 25: 1365-1377.
28. Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006; 51: 2165-2169.
29. Moshkovska T, Stone M, Baker R, et al. Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis. Inflamm Bowel Dis. 2008; 14: 763-768.
30. D'Inca R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008; 27: 166-172.
31. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98: 1535-1544.
32. Nguyen GC, LaVeist TA, Harris ML, et al. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 1233-1239.
33. Horne R, Parham R, Driscoll R, et al. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 837-844.
34. Cerveny P, Bortlik M, Kubena A, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis. 2007; 13: 1244-1249.
35. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007; 102: 1417-1426.